Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet Holdings (NYSE: ZBH) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 p.m. ET. Presenters include President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. A live webcast will be available on Zimmer Biomet's Investor Relations website and archived for future viewing. Zimmer Biomet is a leader in musculoskeletal healthcare, designing and marketing a wide range of orthopedic and surgical products globally.
Zimmer Biomet Holdings and Hospital for Special Surgery (HSS) have announced an exclusive agreement to implement HSS Orthopedic Care Pathways via the mymobility platform with Apple Watch. This collaboration aims to enhance remote patient care through state-of-the-art surgical care protocols. By utilizing Apple Watch's sensors, physicians can monitor patients' activity and recovery metrics, facilitating virtual doctor-patient interactions and potentially lowering care costs. The new pathways will be available globally in early 2021.
Zimmer Biomet Holdings (NYSE: ZBH) has launched the Zimmer Biomet Foundation, a philanthropic organization aimed at supporting diverse and underserved communities. The Foundation will focus on STEM education, community health, and disaster relief. Zimmer Biomet pledges $2 million over three years in partnership with the NAACP to combat racial injustice and promote diversity. This initiative is part of a larger commitment of at least $5 million over five years towards anti-racism and diversity efforts. The Foundation will also match employee contributions to non-profits.
On December 1, 2020, ZBH announced the completion of its acquisition of A&E Medical Corporation for $150 million in cash at closing and $100 million payable in 2021. This acquisition enhances Zimmer Biomet's portfolio with sternal closure devices, including sutures and rigid fixation systems. The deal is expected to have an immaterial impact on net earnings for 2020. The global sternal closure market is growing at a high single-digit percentage rate annually, indicating potential for expanded revenue through this integration.
Zimmer Biomet Holdings (NYSE: ZBH) announced that President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the 2020 Evercore ISI HealthCONx Conference on December 1, 2020, at 10:30 a.m. ET. Upadhyay will also present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, at 11:00 a.m. ET. Live webcasts can be accessed via the Investor Relations website and will be archived for future viewing. Founded in 1927, Zimmer Biomet is a leader in musculoskeletal healthcare, providing innovative solutions for orthopedic care globally.
Zimmer Biomet reported third quarter 2020 net sales of $1.929 billion, a 2.0% increase year-over-year. Net earnings were $242.5 million, with diluted earnings per share at $1.16, down 44.2% compared to last year. Adjusted EPS rose by 2.3% to $1.81. The company completed two acquisitions totaling $80 million, enhancing its product offerings in the operating room and arthroscopy markets. However, they face ongoing uncertainties due to COVID-19, impacting guidance for future quarters.
Zimmer Biomet announced preliminary results from a clinical trial evaluating its mymobility platform with Apple Watch. Presented at the AAHKS annual meeting, the trial involved 448 patients undergoing knee arthroplasty. Results showed mymobility yielded similar early outcomes compared to traditional care. Notably, mymobility patients required significantly fewer physical therapy visits (p<0.0001) and reported lower emergency visits and readmission rates, although these were not statistically significant. The platform aims to enhance remote care management while potentially lowering overall healthcare costs.
Zimmer Biomet, a leader in musculoskeletal healthcare, will present at the Stifel Virtual Healthcare Conference on November 17 at 11:20 a.m. ET. The presentation will be led by President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. Investors can access the live webcast at Zimmer Biomet's Investor Relations website, where the presentation will also be archived for replay. Founded in 1927, Zimmer Biomet designs and markets a broad range of orthopedic and surgical products worldwide.
Zimmer Biomet Holdings (NYSE: ZBH) announced that Liane Teplitsky, VP and General Manager of Worldwide Robotics, will present at the SVB Leerink CybeRx Series: Devices & DNA conference on November 12, 2020, at 12:30 p.m. ET. A live webcast of the presentation will be available on Zimmer Biomet's Investor Relations website and will be archived for replay. Established in 1927 and based in Warsaw, Indiana, Zimmer Biomet is a leader in musculoskeletal healthcare, offering a range of orthopedic and surgical products. For more details, visit zimmerbiomet.com.
Zimmer Biomet has launched a multimedia campaign titled Don't Let Pain Gain on You to encourage individuals who have postponed joint replacement surgeries due to the COVID-19 pandemic to consult with healthcare professionals. A recent survey reveals that 48% of potential candidates delayed treatment, with 53% waiting over a year. The campaign seeks to empower these candidates, highlighting that 82% of patients who underwent surgery felt safe during the process. The initiative aims to address the increasing pain and mobility issues faced by those delaying surgery.